> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# International Labs Recalls Mislabeled Clopidogrel
- URL: https://www.fdaweb.com/international-labs-recalls-mislabeled-clopidogrel/
- Published: 2020-04-17T12:00:00.000Z
- Updated: 2026-09-14T16:11:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146591

International Laboratories has recalled one lot (Lot# 117099A) of clopidogrel tablets 75 mg due to a mislabeling. The product may contain clopidogrel 75mg or simvastatin Tablets 10 mg, according to a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/international-laboratories-llc-issues-voluntary-nationwide-recall-one-1-lot-clopidogrel-tablets-usp?utm%5Fcampaign=FDA%20MedWatch%20Clopidogrel%20Tablets%2C%2075&utm%5Fmedium=email&utm%5Fsource=Eloqua). Missed doses of clopidogrel increases the risk of heart attack and stroke, while unintentional ingestion of simvastatin, a cholesterol-lowering drug, could include common side effects associated with its use and may cause fetal harm if administered to a pregnant woman, it says. Clopidogrel is a platelet inhibitor (blood thinner) indicated for use in patients with acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease.